



03-13-05 1AP5 Rec'd PCT/PTO 09 MAR 2006 T

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	REIMER	Examiner:	Unknown
Serial No.:	10/551303	Group Art Unit:	Unknown
Filed:	September 27, 2005	Docket:	12695.0017USWO
Confirmation No.:	Unknown	Notice of Allow.	N/A
		Date:	
Due Date:	N/A		
Title:	COMPOSITIONS FOR TREATING ANGINA		

CERTIFICATE UNDER 37 CFR 1.10:  
"Express Mail" mailing label number: EV 841297695 US  
Date of Deposit: March 9th, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450

By: [Signature]  
Name: John Junkers

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**23552**  
PATENT TRADEMARK OFFICE

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 11 Reference(s)
- ☒ Other: International Search Report
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.  
P.O. Box 2903  
Minneapolis, MN 55402-0903  
612.332.5300

By: [Signature]  
Name: Brian R. Dorn  
Reg. No.: 57,395  
BRD/ncb



IN 10/551303

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	REIMER	Examiner:	Unknown
Serial No.:	10/551303	Group Art Unit:	Unknown
Filed:	September 27, 2005	Docket No.:	12695.0017USWO
Title:	COMPOSITIONS FOR TREATING ANGINA		

<p><u>CERTIFICATE UNDER 37 CFR 1.10:</u> "Express Mail" mailing label number EV 841297698 US Date of Deposit: <u>March 9th, 2006</u></p> <p>I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450</p> <p>By: <u>[Signature]</u> Name: John Junkers</p>
---

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. Enclosed for the Examiner's information is a copy of the International Search Report. At least some of the references were cited in an International Search Report mailed July 26, 2004.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. §1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

A concise explanation of the relevance of each non-English language document or other information is as follows (37 C.F.R. §1.98(a)(3)):

The French document "Urbain et al" was cited in the International Search report as a type "A" document, meaning the document is defining the general state of the art which is not considered to be of particular relevance.

An English abstract has been provided for the French language article "Wolf et al".

An English abstract has been provided for the German language article "Rudzite et al."

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.




Dated: March 9, 2006

BRD/ncb

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, MN 55402-0903  
(612)332.5300

By:   
Brian R. Dorn  
Reg. No.: 57,395

FORM 1449\*

## INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

12695.0017USWO


Application Number:

10/551303

Applicant: REIMER

Filing Date: September 27,  
2005

Group Art Unit: Unknown



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,051,587	04-18-2000	Dakashinamurti et al.			
	6,043,259	03-28-2000	Dhalla et al.			
	6,339,085	01-15-2002	Haque			
	4,374,841	02-22-1983	Descamps et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	2004/017916 A2	03-2004	WIPO				
	2 075 983 A	11-1981	United Kingdom				
	01/64692 A1	09-2001	WIPO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	BERGE et al. "Pharmaceutical Salts" Journal of Pharmaceutical Sciences, Vol. 66 No. 1 (1977) P. 1-16
	WOLFF et al. " Metabolic Approaches to the Treatment of Ischemic Heart Disease: The Clinicians' Perspective", Heart Failure Reviews, 7, (2002) P. 187-203
	RUPP et al, " The Use of Partial Fatty Acid Oxidation inhibitors for Metabolic Therapy of Angina Pectoris and Heart Failure", Herz 2002; 27 (7) : P. 621-636
	STANLEY W.C. "Partial Fatty Acid Oxidation Inhibitors for Stable Angina" Expert Opinions Investigational Drugs, 2002, May: 11(5) P. 615-629
	CHASAN-TABER et al. " A Prospective Study of Folate and Vitamin B <sub>6</sub> and Risk of Myocardial Infarction in US Physicians" Journal of American College of Nutrition, Vol 15, No. 2, 1996: P. 136-143
	URBAIN et al. " Potential Cardiovascular derivatives of Piperazinoisopropanoloxypyridoxine" European J. of Medicinal Chem., 17 (4) P. 359-364, 1982
	WOLF et al. " Iatrogenic oxalic lithiasis caused by pyridoxilate" Nephrologie, 6(5) (1985) P.225-227
	RUDZITE et al. "Peculiarities of nicotinic acid formation in coronary heart disease with special reference to heart arrhythmias" Z Gesamte Inn Med. 1988 Feb 1; 43(3): P. 60-65

23552

PATENT TRADEMARK OFFICE

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.